title: Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients: a systematic review of quantitative studies.
abstract: Cancer-related fatigue (CRF) is the most common psychosomatic distress experienced by cancer patients before, during and after chemotherapy. Its impact on functional status and Health Related Quality of Life is a great concern among patients, healthcare professionals and researchers. The primary objective of this systematic review is to determine whether the different chemotherapies affect the association of CRF with individual pro- and anti-inflammatory cytokines. The PRISMA statement guideline has been followed to systematically search and screen article from PubMed and Embase.
  
  
  
  This review has examined 14 studies which included a total of 1312 patients. These studies assayed 20 different kinds of cytokines. The cytokines interleukin-6, interleukin-1RA, TGF-β and sTNF-R2 were associated with CRF in patients receiving anthracycline-based chemotherapy. However, only interleukin-13 was identified in the taxane-based chemotherapy. Similarly, different sets of cytokines were linked with CRF in patients with chemotherapy regimens containing platinum, cyclophosphamides, topotecan or bleomycin.
  
  
  
  This review has identified that cytokines are differentially linked with CRF according to the various types of chemotherapy regimens.
authors.affiliation: aDepartment of Pharmacy, National University of Singapore, Singapore bDepartment of Pharmacy, National Cancer Centre Singapore, Singapore cQueensland University of Technology, Brisbane Queensland, Australia dRoyal Brisbane and Women's Hospital, Herston, QLD, Australia eDuke-NUS Medical School Singapore, Singapore.
authors.forename: Tewodros
authors.initials: T
authors.lastname: Eyob
authors.forename: Terence
authors.initials: T
authors.lastname: Ng
authors.forename: Raymond
authors.initials: R
authors.lastname: Chan
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chan
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers; D016207:Cytokines / Q000096:biosynthesis*; D005221:Fatigue / Q000209:etiology*; D006801:Humans; D015850:Interleukin-6; D009369:Neoplasms / Q000150:complications*; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D016207:Cytokines; D015850:Interleukin-6